RadNet (RDNT) Expected to Announce Earnings on Monday

RadNet (NASDAQ:RDNT - Get Free Report) is anticipated to release its Q1 2025 earnings data before the market opens on Monday, May 12th. Analysts expect RadNet to post earnings of ($0.16) per share and revenue of $442.98 million for the quarter. RadNet has set its FY 2025 guidance at EPS.

RadNet (NASDAQ:RDNT - Get Free Report) last posted its quarterly earnings results on Thursday, February 27th. The medical research company reported $0.22 EPS for the quarter, beating the consensus estimate of $0.21 by $0.01. RadNet had a positive return on equity of 4.29% and a negative net margin of 0.25%. The firm had revenue of $477.10 million during the quarter, compared to analysts' expectations of $459.42 million. On average, analysts expect RadNet to post $1 EPS for the current fiscal year and $1 EPS for the next fiscal year.

RadNet Stock Performance

Shares of NASDAQ:RDNT traded down $0.61 during trading on Friday, hitting $55.77. 1,993,767 shares of the stock were exchanged, compared to its average volume of 671,730. The company's fifty day simple moving average is $50.77 and its 200-day simple moving average is $63.41. The company has a debt-to-equity ratio of 0.89, a quick ratio of 2.16 and a current ratio of 2.16. The company has a market capitalization of $4.18 billion, a price-to-earnings ratio of -796.60 and a beta of 1.46. RadNet has a 1-year low of $45.00 and a 1-year high of $93.65.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on RDNT shares. Truist Financial lowered their price target on shares of RadNet from $88.00 to $74.00 and set a "buy" rating on the stock in a report on Friday, April 11th. Jefferies Financial Group dropped their price target on shares of RadNet from $100.00 to $80.00 and set a "buy" rating for the company in a research report on Wednesday, January 15th. StockNews.com raised RadNet to a "sell" rating in a report on Wednesday, March 19th. Barclays dropped their target price on RadNet from $74.00 to $60.00 and set an "overweight" rating for the company in a report on Monday, March 24th. Finally, Raymond James raised RadNet from an "outperform" rating to a "strong-buy" rating and decreased their price target for the company from $85.00 to $65.00 in a research note on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, three have given a buy rating and two have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Buy" and a consensus target price of $69.75.

Insiders Place Their Bets

In related news, COO Norman R. Hames sold 5,000 shares of the business's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $49.79, for a total value of $248,950.00. Following the completion of the transaction, the chief operating officer now owns 261,959 shares in the company, valued at $13,042,938.61. The trade was a 1.87 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director David L. Swartz sold 25,000 shares of the stock in a transaction on Friday, March 7th. The shares were sold at an average price of $50.84, for a total value of $1,271,000.00. Following the completion of the transaction, the director now owns 174,067 shares in the company, valued at $8,849,566.28. The trade was a 12.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,000 shares of company stock valued at $1,926,730. Insiders own 5.12% of the company's stock.

RadNet Company Profile

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. The company operates in two segments: Imaging Centers and Artificial Intelligence. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.